Clinuvel has submitted NEURACTHEL Instant for regulatory review in three initial European Union markets, opening a potential pathway for its second pharmaceutical product. The decentralised review is expected to take 300 days, excluding clock stops, but the product is not yet approved anywhere.
- Marketing authorisation dossier filed for NEURACTHEL Instant
- Three initial EU member states selected as launch markets
- Decentralised procedure expected to run for 300 days excluding clock stops
- Validation and initial formal feedback expected in about four months
- Further UK, EU and US submissions remain under evaluation
NEURACTHEL Instant enters European review
CLINUVEL PHARMACEUTICALS LTD (ASX:CUV; Nasdaq: CUVL) has filed the marketing authorisation dossier for NEURACTHEL Instant with regulators in three initial European Union member states. The submission marks the first regulatory filing for the company’s second pharmaceutical product and, if approved, could allow commercialisation as a prescription medicine in up to three EU markets.
NEURACTHEL Instant is a branded generic formulation of tetracosactide, a synthetic 24-amino acid analogue of the naturally occurring adrenocorticotropic hormone, or ACTH. ACTH products are used in Europe both as therapies and diagnostic tools for adrenal insufficiency, while synthetic ACTH products are approved in the United States for 19 conditions, including infantile spasms and acute exacerbations of multiple sclerosis.
Three launch markets selected for commercial fit
Clinuvel said it chose the initial EU markets based on routine ACTH use, prescriber demand, pricing infrastructure and reported product shortages. The company also considered overlap with the existing distribution network for SCENESSE, its approved afamelanotide treatment, allowing it to use established commercial infrastructure.
The filing does not identify the three countries or the reference member state leading the assessment. It also gives no expected launch revenue, and NEURACTHEL Instant remains unapproved in every country. The company said the global ACTH market is estimated at US$1.3 billion annually, a figure that describes the wider market rather than any forecast for Clinuvel.
A 300-day regulatory path with early feedback ahead
The application is proceeding through the European decentralised procedure, under which a reference member state leads a parallel review involving other participating EU countries. Following dossier validation, the process is intended to take 300 days, excluding periods when the regulatory clock is stopped for questions or additional information, with a final position expected around day 270.
Chief Scientific Officer Dennis Wright said the company expects validation and first formal feedback in about four months. Further filings in the United Kingdom and other EU member states are being assessed according to the viability of potential commercial programs, while the timing of a United States Food and Drug Administration submission is also under review.
The immediate milestone is therefore validation, not approval. That distinction matters: the filing establishes a defined regulatory route for NEURACTHEL Instant, but the eventual label, timing, commercial reach and economics remain dependent on the review and any follow-up submissions.
Bottom Line?
Validation and first regulator feedback in roughly four months should provide the next meaningful test of whether NEURACTHEL Instant can advance from filing to a viable European launch.
Questions in the middle?
- Which three EU member states will conduct the initial review and serve as the first commercial markets?
- Will regulators request additional evidence or changes that extend the stated 300-day procedure?
- How much commercial value can Clinuvel capture from ACTH shortages and its existing SCENESSE distribution infrastructure?